Cas:87597-83-9 2-amino-6-nitro-1H-quinazolin-4-one manufacturer & supplier

Chemical Name:2-amino-6-nitro-1H-quinazolin-4-one

CAS.NO:87597-83-9

Synonyms:2-amino-4-hydroxy-6-nitroquinazoline;2-Amino-6-nitro-4(3H)-quinazolone;2-Amino-6-nitroquinazolin-4(3H)-one

Molecular Formula:C₈H₆N₄O₃

Molecular Weight:206.15800

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:118.58000

Exact Mass:206.04400

LogP:1.27910

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-amino-4-hydroxy-6-nitroquinazoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Amino-6-nitroquinazolin-4(3H)-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-amino-4-hydroxy-6-nitroquinazoline Use and application,2-Amino-6-nitroquinazolin-4(3H)-one technical grade,usp/ep/jp grade.

Related News: The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. 2-amino-6-nitro-1H-quinazolin-4-one manufacturer The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 2-amino-6-nitro-1H-quinazolin-4-one supplier The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. 2-amino-6-nitro-1H-quinazolin-4-one vendor The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 2-amino-6-nitro-1H-quinazolin-4-one factory Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study.